Tekla Capital Management’s Myovant Sciences Ltd. MYOV Stock Holding History

Tekla Capital Management’s Portfolio MYOV Stock Details MYOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-150,471	Closed	-$3.2M	–	190
2018 Q1	$3.2M	Sell	150,471 -249,529	-62%	-$3.8M	0.12%	114
2017 Q4	$5.06M	Hold	400,000	–	–	0.2%	92
2017 Q3	$6.19M	Hold	400,000	–	–	0.22%	79
2017 Q2	$4.68M	Hold	400,000	–	–	0.17%	89
2017 Q1	$4.7M	Hold	400,000	–	–	0.18%	87
2016 Q4	$4.98M	Buy	+400,000	New	+$4.63M	0.21%	80

Other funds holding MYOV

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tekla Capital Management's MYOV Position: Q2 2018 in Review

Tekla Capital Management sold out of Myovant Sciences Ltd. (MYOV) in Q2 2018, closing a stake of 150,471 shares — an estimated $3.2M sold.

Tekla Capital Management first reported a position in MYOV in Q4 2016 and held it in 6 quarters. The position peaked at $6.19M in Q3 2017. 31 funds tracked by Wall St. Rank hold MYOV as of Q2 2018.

Tekla Capital Management reported no remaining Myovant Sciences Ltd. position as of Q2 2018 after selling out during the quarter.
Tekla Capital Management sold 150,471 Myovant Sciences Ltd. shares in Q2 2018, an estimated $3.2M.
Tekla Capital Management first reported a position in Myovant Sciences Ltd. in Q4 2016 and held it in 6 quarters.
Tekla Capital Management's Myovant Sciences Ltd. position peaked at $6.19M in Q3 2017.
31 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q2 2018.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.